AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...
AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...
Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...